System and method for rapidly cooling cardiac arrest patient

Information

  • Patent Grant
  • 8353893
  • Patent Number
    8,353,893
  • Date Filed
    Wednesday, March 7, 2007
    17 years ago
  • Date Issued
    Tuesday, January 15, 2013
    11 years ago
Abstract
A combined occlusion/infusion catheter is placed in the aorta of a cardiac arrest patient to occlude the aorta at a location just above the renal arteries/celiac trunk while rapidly infusing a liter or more of cold saline into the aorta below the occlusion. This flushes white cells from the bowel (now placed into a state of hypothermic stasis) induces hypothermia in the whole body, with perfusion pressure of the cold fluid maximized to the brain.
Description
I. FIELD OF THE INVENTION

The present invention relates generally to systems and methods for rapidly cooling cardiac arrest patients.


II. BACKGROUND OF THE INVENTION

It has been discovered that the medical outcome for a patient suffering from severe brain trauma or from ischemia caused by stroke or heart attack or cardiac arrest is improved if the patient is cooled below normal body temperature (37° C.). Furthermore, it is also accepted that for such patients, it is important to prevent hyperthermia (fever) even if it is decided not to induce hypothermia.


As understood herein it may be advantageous, particularly for cardiac arrest patients, to immediately and rapidly perfuse one or more critical organs with cold fluid. The present invention also understands that owing to the structure of the arterial system, it may be necessary to provide a means to maintain the cold fluid in a desired body location for at least a limited time. With these critical recognitions in mind, the invention herein is provided.


SUMMARY OF THE INVENTION

A method includes advancing a combined occlusion/infusion catheter into the aorta of a cardiac arrest patient and then using the catheter to occlude the aorta at a location just above the renal arteries/celiac trunk. The catheter is then used to infuse cold saline into the aorta below the occlusion.


In non-limiting implementations between one and four liters of cold saline are infused through the catheter into the aorta, preferably at a rate of approximately one liter per minute.


As set forth further below, in some implementations the catheter can include at least an upper balloon that is inflatable once inside the aorta to substantially completely occlude the aorta. Also, the catheter may include a lower balloon that can be inflated once inside the aorta to substantially completely occlude the aorta at a location just below the lower mesenteric artery. Preferably, the catheter is inserted and used as rapidly as possible after the cardiac arrest if the patient is comatose regardless of the state of spontaneous circulation in the patient.


In another aspect, a catheter system includes an elongated flexible body and at least an upper balloon on the body at or near a distal end thereof. An inflation lumen is formed in the body and communicates with the balloon to move the balloon from a deflated configuration, wherein the balloon can be advanced into the aorta of a patient above the renal arteries, to an inflated configuration, wherein the balloon is sufficiently large to substantially completely occlude the aorta above the renal arteries. An infusion lumen is also formed on the body and terminates at a port below the upper balloon. With this structure, a source of saline having a temperature of less than five degrees Centigrade can be placed in fluid communication with the infusion lumen and a source of inflation fluid can be placed in fluid communication with the inflation lumen.


In still another aspect, a catheter is advanced into a patient's aorta after the patient has suffered cardiac arrest regardless of the state of spontaneous circulation. The method below may also be used with non-arrest myocardial infarction patients. Regardless, an upper balloon in a deflated configuration is advanced to a location just above the renal arteries and celiac trunk and then inflated to occlude the lower aorta above the renal arteries and celiac trunk. With the aorta blocked by the upper balloon, cold biocompatible fluid is infused through the catheter into the aorta below the balloon, after which the balloon is deflated and the catheter withdrawn.


The details of the present invention, both as to its structure and operation, can best be understood in reference to the accompanying drawings, in which like reference numerals refer to like parts, and in which:





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a schematic diagram showing a non-limiting catheter engaged with the arterial system of a patient immediately post-cardiac arrest; and



FIG. 2 is a cross-sectional diagram of the catheter shown in FIG. 1.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Referring initially to FIG. 1, a catheter 10 is shown advanced into the arterial system of a patient who has suffered cardiac arrest. It is preferred that the catheter 10 is inserted and used as described below as rapidly as possible after the arrest if the patient is comatose regardless of the state of spontaneous circulation.



FIG. 1 labels relevant branches of the aorta of the patient to give perspective in the preferred placement of the catheter 10. An upper balloon 12 in a deflated configuration is advanced into the lower aorta to a location just above the renal arteries and celiac trunk as shown and then inflated to occlude, preferably completely, the lower aorta above the renal arteries and celiac trunk.


In non-limiting implementations the catheter 10 may further include a lower balloon 14 located on the catheter 10 (assuming a standard adult anatomy) to be disposed below the inferior mesenteric artery when the upper balloon 12 is positioned as described above. Thus, it is to be understood that the terms “upper” and “lower” are intended to convey the locations of the balloons with respect to each other relative to the patient's anatomy when the balloons are operatively disposed in the patient.


Once inflated, the lower balloon 14 thus occludes, preferably completely, flow of the cold fluid described below to the lower extremities and other organs below the level of the lower mesenteric artery thereby ensuring that the majority of the cold fluid flows through the enteric vascular bed. When a lower balloon 14 is not used, a higher volume of infused fluid than described below may be used.


As shown in FIG. 1, in non-limiting implementations the catheter 10 can be advanced into the location shown through a femoral artery, the associated iliac artery, and into and upward in the aorta. Other vessels may be used for insertion.


Once the upper balloon 12 (and if provided, the lower balloon 14) are positioned as shown in FIG. 1, the balloons are inflated with saline or other solution to fully occlude the aorta in the locations shown. The inflation fluid may be infused from a suitable inflation fluid source 16 that can have a pump.


Then, with the aorta blocked cold biocompatible fluid such as saline is infused through the catheter 10 to emerge at the below-described distal port of the catheter 10 into the aorta. The cold fluid may be infused from a source 18 of cold fluid that can include a pump. It is preferred that the infusion of the cold fluid is rapid, approximately one liter per minute or faster, and for a relatively short period of time, e.g., two to four minutes, for a total volume of between two to four liters of cold fluid. It is preferred that the infusion fluid be very cold, e.g., when saline is used the temperature of the saline may be less than ten degrees Centigrade, more preferably less than five degrees Centigrade, and more preferably still about one to two degrees Centigrade.


After infusing the cold fluid into the aorta, the balloon(s) 12, 14 are deflated and spontaneous circulation is resumed, assuming the heart has not already been brought out of arrest. To this end, a source 20 of vacuum may be connected to the same line through which inflation fluid was infused and actuated to rapidly deflate the balloons. The catheter 10 is then withdrawn from the body.



FIG. 2 shows additional details of the non-limiting catheter 10 shown in FIG. 1. The catheter 10 includes a flexible elongated plastic body 22 onto which the balloons 12, 14 may be, e.g., bonded. The body 22 can be formed with at least two lumens, and in the embodiment shown is formed with an inflation/deflation lumen 24 and an infusion lumen 26 that terminates in an infusion port 28 distal to the lower balloon 14 and proximal to the upper balloon 12 as shown (i.e., located axially between the balloons). It is to be understood that the source 16 of inflation fluid and the source 20 of vacuum shown in FIG. 1 are connected to the inflation/deflation lumen 24. On the other hand, the source 18 of cold fluid shown in FIG. 1 is connected to the infusion lumen 26, so that the cold fluid from the source 18 can flow through the infusion lumen 26 and exit the catheter 10 through the infusion port 28 into the aorta, below the upper balloon 12 and above the lower balloon 14 (and hence into the celiac artery, the upper mesenteric artery, and the lower mesenteric artery.


To provide a pathway for inflation fluid communication from the inflation/deflation lumen 24 in the body 22 to the interior of the balloons 12, 14, respective inflation/deflation ports 30, 32 are formed in the catheter body 22 as shown. The ports 30, 32 extend completely between the inflation/deflation lumen 24 and the interiors of the balloons 12, 14. More than one port per balloon may be used to promote rapid inflation and deflation.


If desired, within the catheter 10 at or near the axial location of the upper balloon 12 (e.g., at the distal tip of the catheter 10) an ultrasonic repeater 34 such as a crystal can be mounted by, e.g., bonding the repeater 34 to the body 22. In accordance with ultrasonic locating techniques known in the art, an ultrasound transponder (not shown) can be disposed on the skin of the patient immediately below the edge of the ribs and in the anterior midline. The transponder can be activated to transmit an ultrasonic pulse that has a maximized return immediately above the location of the repeater 34, and an indication of the maximized return can be presented to the surgeon. In this manner, the catheter 10 may be properly located above the visceral arteries.


The catheter 10 may be coated with biocompatible coatings (e.g., heparin) to reduce clotting and/or with antimicrobial coatings to reduce the risk of infection.


With the above disclosure in mind, it will now be appreciated that use of the catheter 10 as disclosed, owing to infusing cold saline into the arteries between the balloons 12, 14, acts to flush white cells from the bowel, as well as to place the bowel into a state of hypothermic stasis. At the same time, hypothermia induction in the whole body advantageously is commenced, with perfusion pressure of the cold fluid maximized to the brain.


While the particular SYSTEM AND METHOD FOR RAPIDLY COOLING CARDIAC ARREST PATIENT is herein shown and described in detail, it is to be understood that the subject matter which is encompassed by the present invention is limited only by the claims.

Claims
  • 1. A method comprising: advancing an occlusion/infusion catheter into the aorta of a cardiac arrest patient;using the catheter to occlude the aorta at an anatomic location just above the renal arteries/celiac trunk; andusing the catheter to infuse cold saline into the aorta anatomically below the occlusion caused by the catheter.
  • 2. The method of claim 1, comprising infusing between one and four liters of cold saline into the aorta.
  • 3. The method of claim 2, comprising infusing the saline at a rate of approximately one liter per minute.
  • 4. The method of claim 1, wherein the catheter includes at least an upper balloon inflatable once inside the aorta to substantially completely occlude the aorta.
  • 5. The method of claim 1, wherein the catheter includes at least a lower balloon inflatable once inside the aorta to substantially completely occlude the aorta at a location just below the lower mesenteric artery.
  • 6. The method of claim 1, wherein the catheter is inserted and used as rapidly as possible after the cardiac arrest if the patient is comatose regardless of the state of spontaneous circulation in the patient.
  • 7. The method of claim 1, further comprising using ultrasound to locate the catheter.
  • 8. A catheter system, comprising: an elongated flexible body;at least an upper balloon on the body at or near a distal end thereof;at least one inflation lumen formed in the body and communicating with the balloon to move the balloon from a deflated configuration, wherein the balloon can be advanced into the aorta of a patient to a location that is anatomically above the renal arteries, to an inflated configuration, wherein the balloon is sufficiently large to substantially completely occlude the aorta above the renal arteries and below the heart;at least one infusion lumen formed on the body and terminating at a port proximal to the upper balloon and anatomically below the balloon when the balloon is inflated and positioned above the renal arteries and below the heart;a source of saline having a temperature of less than five degrees Centigrade and communicating with the infusion lumen; anda source of inflation fluid communicating with the inflation lumen.
  • 9. The system of claim 8, further comprising a source of vacuum communicating with the inflation lumen to move the balloon from the inflated to the deflated configuration.
  • 10. The system of claim 8, further comprising a lower balloon on the body and movable between a deflated configuration, wherein the lower balloon can be advanced into the aorta of a patient to a position just below the lower mesenteric artery, and an inflated configuration, wherein the lower balloon is sufficiently large to substantially completely occlude the aorta just below the lower mesenteric artery, the port being formed between the balloons.
  • 11. The system of claim 8, further comprising an ultrasonic repeater located on the catheter body adjacent the balloon.
  • 12. A method, comprising: advancing a catheter into a patient's aorta after the patient has suffered cardiac arrest regardless of the state of spontaneous circulation;positioning an upper balloon while in a deflated configuration to a location just above the renal arteries and celiac trunk;inflating the upper balloon to occlude the lower aorta above the renal arteries and celiac trunk;with the aorta blocked by the upper balloon, infusing cold biocompatible fluid through the catheter into the aorta anatomically below the upper balloon;deflating the balloon; andwithdrawing the catheter from the patient.
  • 13. The method of claim 12, comprising infusing the cold fluid at approximately one liter per minute or faster for two to four minutes.
  • 14. The method of claim 13, wherein the temperature of the cold fluid is no more than five degrees Centigrade.
  • 15. The method of claim 14, wherein the catheter includes a lower balloon disposed below the inferior mesenteric artery when the upper balloon is positioned at a location just above the renal arteries and celiac trunk, and the method comprises inflating the lower balloon to occlude flow of the cold fluid to aorta locations below the lower mesenteric artery, thereby ensuring that a majority of the cold fluid flows through the enteric vascular bed.
  • 16. The method of claim 15, comprising positioning the catheter using ultrasound.
US Referenced Citations (239)
Number Name Date Kind
7356 Atwood May 1850 A
62961 Keyser Mar 1867 A
76315 Evard Apr 1868 A
111129 Macauley Jan 1871 A
114614 Smith May 1871 A
117129 Walker Jul 1871 A
123142 Beckwith Jan 1872 A
127535 Whittingham Jun 1872 A
135631 Corser Feb 1873 A
164166 Gordon Jun 1875 A
171129 Hermance Dec 1875 A
206074 Beckwith Jul 1878 A
5207640 Hattler May 1993 A
5230862 Berry et al. Jul 1993 A
5269758 Taheri Dec 1993 A
5271743 Hattler Dec 1993 A
5279598 Sheaff Jan 1994 A
5437633 Manning Aug 1995 A
5450516 Pasquali et al. Sep 1995 A
5470659 Baumgart et al. Nov 1995 A
5474533 Ward et al. Dec 1995 A
5478309 Sweezer et al. Dec 1995 A
5678570 Manning Oct 1997 A
5725949 Pasquail et al. Mar 1998 A
5735809 Gorsuch Apr 1998 A
5755690 Saab May 1998 A
5769812 Stevens et al. Jun 1998 A
5792094 Stevens et al. Aug 1998 A
5837003 Ginsburg Nov 1998 A
5876667 Gremel et al. Mar 1999 A
5879329 Ginsburg Mar 1999 A
5916193 Stevens et al. Jun 1999 A
5989238 Ginsburg Nov 1999 A
6004289 Saab Dec 1999 A
6019783 Philips Feb 2000 A
6042559 Dobak, III Mar 2000 A
6096068 Dobak Aug 2000 A
6110168 Ginsburg Aug 2000 A
6126684 Gobin Oct 2000 A
6146411 Noda Nov 2000 A
6149670 Worthen et al. Nov 2000 A
6149673 Ginsburg Nov 2000 A
6149676 Ginsburg Nov 2000 A
6149677 Dobak, III Nov 2000 A
6165207 Balding Dec 2000 A
6224624 Lasheras May 2001 B1
6231594 Dae May 2001 B1
6231595 Dobak May 2001 B1
6235048 Dobak May 2001 B1
6238428 Werneth May 2001 B1
6245095 Dobak et al. Jun 2001 B1
6251129 Dobak Jun 2001 B1
6251130 Dobak Jun 2001 B1
6254626 Dobak Jul 2001 B1
6264679 Keller Jul 2001 B1
6287326 Pecor Sep 2001 B1
6290717 Philips Sep 2001 B1
6299599 Pham et al. Oct 2001 B1
6306161 Ginsburg Oct 2001 B1
6312452 Dobak et al. Nov 2001 B1
6325818 Werneth Dec 2001 B1
6338727 Noda et al. Jan 2002 B1
6364899 Dobak Apr 2002 B1
6368304 Aliberto Apr 2002 B1
6379378 Werneth Apr 2002 B1
6383210 Magers et al. May 2002 B1
6393320 Lasersohn et al. May 2002 B2
6405080 Lasersohn Jun 2002 B1
6409747 Gobin Jun 2002 B1
6416533 Gobin Jul 2002 B1
6419643 Shimada Jul 2002 B1
6428563 Keller Aug 2002 B1
6432124 Worthen Aug 2002 B1
6436130 Philips Aug 2002 B1
6436131 Ginsburg Aug 2002 B1
6440158 Saab Aug 2002 B1
6447474 Balding Sep 2002 B1
6450987 Kramer Sep 2002 B1
6450990 Walker Sep 2002 B1
6451004 Peters Sep 2002 B1
6451045 Walker Sep 2002 B1
6454792 Noda Sep 2002 B1
6454793 Evans Sep 2002 B1
6458150 Evans Oct 2002 B1
6460544 Worthen Oct 2002 B1
6464716 Dobak Oct 2002 B1
6468296 Dobak Oct 2002 B1
6471717 Dobak Oct 2002 B1
6475231 Dobak Nov 2002 B2
6478811 Dobak Nov 2002 B1
6478812 Dobak Nov 2002 B2
6482226 Dobak Nov 2002 B1
6491039 Dobak Dec 2002 B1
6491716 Dobak Dec 2002 B2
6494903 Pecor Dec 2002 B2
6497721 Ginsburg Dec 2002 B2
6516224 Lasersohn et al. Feb 2003 B2
6520933 Evans Feb 2003 B1
6527798 Ginsburg Mar 2003 B2
6529775 Whitebook Mar 2003 B2
6530946 Noda Mar 2003 B1
6533804 Dobak Mar 2003 B2
6540771 Dobak Apr 2003 B2
6544282 Dae Apr 2003 B1
6551349 Lasheras Apr 2003 B2
6554797 Worthen Apr 2003 B1
6558412 Dobak May 2003 B2
6572538 Takase Jun 2003 B2
6572638 Dae et al. Jun 2003 B1
6572640 Balding Jun 2003 B1
6576001 Werneth Jun 2003 B2
6576002 Dobak Jun 2003 B2
6581403 Whitebook Jun 2003 B2
6582398 Worthen Jun 2003 B1
6582455 Dobak Jun 2003 B1
6582457 Dae Jun 2003 B2
6585692 Worthen Jul 2003 B1
6585752 Dobak Jul 2003 B2
6589271 Tzeng Jul 2003 B1
6595967 Kramer Jul 2003 B2
6599312 Dobak Jul 2003 B2
6602243 Noda Aug 2003 B2
6602276 Dobak Aug 2003 B2
6607517 Dae Aug 2003 B1
6610083 Keller Aug 2003 B2
6620130 Ginsburg Sep 2003 B1
6620131 Pham Sep 2003 B2
6620188 Ginsburg Sep 2003 B1
6620189 MacHold et al. Sep 2003 B1
6623516 Saab Sep 2003 B2
6635076 Ginsburg Oct 2003 B1
6641602 Balding Nov 2003 B2
6641603 Walker Nov 2003 B2
6645234 Evans et al. Nov 2003 B2
6648906 Lasheras Nov 2003 B2
6648908 Dobak Nov 2003 B2
6652565 Shimada Nov 2003 B1
6656209 Ginsburg Dec 2003 B1
6660028 Magers Dec 2003 B2
6669661 Yee Dec 2003 B1
6673098 MacHold Jan 2004 B1
6676688 Dobak Jan 2004 B2
6676689 Dobak Jan 2004 B2
6676690 Werneth Jan 2004 B2
6679906 Hammack Jan 2004 B2
6679907 Dobak Jan 2004 B2
6682551 Worthen Jan 2004 B1
6685732 Kramer Feb 2004 B2
6685733 Dae Feb 2004 B1
6692488 Dobak Feb 2004 B2
6692519 Hayes Feb 2004 B1
6695873 Dobak Feb 2004 B2
6695874 MacHold Feb 2004 B2
6699268 Kordis Mar 2004 B2
6702783 Dae Mar 2004 B1
6702839 Dae Mar 2004 B1
6702840 Keller Mar 2004 B2
6702841 Nest Mar 2004 B2
6702842 Dobak Mar 2004 B2
6706060 Tzeng Mar 2004 B2
6709448 Walker Mar 2004 B2
6716188 Noda Apr 2004 B2
6716236 Tzeng Apr 2004 B1
6719723 Werneth Apr 2004 B2
6719724 Walker Apr 2004 B1
6719779 Daoud Apr 2004 B2
6726653 Noda Apr 2004 B2
6726708 Lasheras Apr 2004 B2
6726710 Worthen Apr 2004 B2
6733517 Collins May 2004 B1
6740109 Dobak May 2004 B2
6749585 Aliberto Jun 2004 B2
6749625 Pompa Jun 2004 B2
6752786 Callister Jun 2004 B2
6755850 Dobak Jun 2004 B2
6755851 Noda Jun 2004 B2
7258662 Machold et al. Aug 2007 B2
7311725 Dobak, III Dec 2007 B2
7326195 Willard et al. Feb 2008 B2
20010001832 Dobak et al. May 2001 A1
20010007951 Dobak Jul 2001 A1
20010016764 Dobak, III Aug 2001 A1
20010041923 Dobak Nov 2001 A1
20010047196 Ginsburg et al. Nov 2001 A1
20010049545 Lasersohn et al. Dec 2001 A1
20020002394 Dobak, III Jan 2002 A1
20020007203 Gilmartin Jan 2002 A1
20020013569 Sterman et al. Jan 2002 A1
20020016621 Werneth Feb 2002 A1
20020029016 Pham et al. Mar 2002 A1
20020032430 Luo et al. Mar 2002 A1
20020068964 Dobak Jun 2002 A1
20020077680 Noda Jun 2002 A1
20020091429 Dobak Jul 2002 A1
20020111616 Dea Aug 2002 A1
20020151946 Dobak, III Oct 2002 A1
20020177804 Saab Nov 2002 A1
20020183692 Callister Dec 2002 A1
20020193738 Adzich Dec 2002 A1
20020193853 Worthen Dec 2002 A1
20020193854 Dobak, III et al. Dec 2002 A1
20030060762 Zvuloni et al. Mar 2003 A1
20030078641 Dobak, III Apr 2003 A1
20030114835 Noda Jun 2003 A1
20030144714 Dobak, III Jul 2003 A1
20030187489 Dobak, III et al. Oct 2003 A1
20030195465 Worthen Oct 2003 A1
20030195466 Pham Oct 2003 A1
20030195597 Keller Oct 2003 A1
20030216799 Worthen Nov 2003 A1
20030225336 Callister Dec 2003 A1
20030236496 Samson et al. Dec 2003 A1
20040034399 Ginsburg Feb 2004 A1
20040039431 Machold Feb 2004 A1
20040044388 Pham Mar 2004 A1
20040050154 Machold Mar 2004 A1
20040054325 Ginsburg Mar 2004 A1
20040073280 Dae Apr 2004 A1
20040087934 Dobak, III et al. May 2004 A1
20040102825 Daoud May 2004 A1
20040102826 Lasheras et al. May 2004 A1
20040102827 Werneth May 2004 A1
20040106969 Dobak, III et al. Jun 2004 A1
20040111138 Bleam Jun 2004 A1
20040116987 Magers et al. Jun 2004 A1
20040116988 Hammack Jun 2004 A1
20040127851 Noda Jul 2004 A1
20040143312 Samson et al. Jul 2004 A1
20040147987 Ginsburg et al. Jul 2004 A1
20040167467 Harrison et al. Aug 2004 A1
20060036303 Schwartz Feb 2006 A1
20060058859 Merrill Mar 2006 A1
20060064146 Collins Mar 2006 A1
20060095104 Magers et al. May 2006 A1
20060200215 Collins Sep 2006 A1
20060293732 Collins et al. Dec 2006 A1
20070000278 Collins et al. Jan 2007 A1
20070135793 Barbut et al. Jun 2007 A1
20070239135 Barbut Oct 2007 A9
Non-Patent Literature Citations (2)
Entry
Wilhelm Behringer et al., “Rapid Hypothermic Aortic Flush Can Achieve Survival without Brain Damage after 30 Minutes Cardiac Arrest in Dogs”, Anesthesiology 2000; 93:1491-9.
U.S. Appl. No. 60/272,442, Worthen et al.
Related Publications (1)
Number Date Country
20080221553 A1 Sep 2008 US